Funder
DHHS Office of the Secretary
Oak Ridge Institute for Science and Education
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference26 articles.
1. Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
2. Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21(8):E668–78.
3. Cost Estimate. S. 1695: Biologics Price Competition and Innovation Act of 2007. Washington, DC: Congressional Budget Office. 2008.
4. Food and Drug Administration. FDA-Approved Biosimilar Products. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed 31 Jan 2021.
5. Herndon K, Braithwaite J, Berry B, Bourget K. Biosimilar perceptions among healthcare professionals and commercial medical benefit policy analysis in the United States. BioDrugs. 2021. https://doi.org/10.1007/s40259-020-00463-6.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献